Chemoinformaics analysis of 11-beta-H,13-dihydrosantamarine
| Molecular Weight | 250.338 | nRot | 0 |
| Heavy Atom Molecular Weight | 228.162 | nRig | 16 |
| Exact Molecular Weight | 250.157 | nRing | 3 |
| Solubility: LogS | -2.866 | nHRing | 1 |
| Solubility: LogP | 2.992 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 2 |
| Atoms Count | 40 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 18 | No. of Aromatic Carbocycles | 0 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 1 |
| No. of Hydrogen atom | 22 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 2 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 0 |
| nHA | 3 | APOL | 42.1254 |
| nHD | 1 | BPOL | 24.6746 |
| QED | 0.53 |
| Synth | 4.441 |
| Natural Product Likeliness | 3.499 |
| NR-PPAR-gamma | 0.006 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0 |
| Pgp-sub | 0.017 |
| HIA | 0.102 |
| CACO-2 | -4.523 |
| MDCK | 0.0000336 |
| BBB | 0.852 |
| PPB | 0.616318 |
| VDSS | 1.104 |
| FU | 0.351398 |
| CYP1A2-inh | 0.113 |
| CYP1A2-sub | 0.319 |
| CYP2c19-inh | 0.027 |
| CYP2c19-sub | 0.673 |
| CYP2c9-inh | 0.02 |
| CYP2c9-sub | 0.214 |
| CYP2d6-inh | 0.011 |
| CYP2d6-sub | 0.438 |
| CYP3a4-inh | 0.23 |
| CYP3a4-sub | 0.27 |
| CL | 18.503 |
| T12 | 0.1 |
| hERG | 0.017 |
| Ames | 0.011 |
| ROA | 0.643 |
| SkinSen | 0.066 |
| Carcinogencity | 0.086 |
| EI | 0.018 |
| Respiratory | 0.821 |
| NR-Aromatase | 0.006 |
| Antiviral | Yes |
| Prediction | 0.873418 |